The treatment combination of intetumumab, an integrin inhibitor, and dasatinib effectively inhibits the migration and proliferation of dasatinib-resistant CRC cells, by suppressing the activation of FAK, PXN and Src [188]. This evidence concerns the gene PXN and colorectal carcinoma.